P1149: Guselkumab improves health-related quality of life as measured by PROMIS-29 in participants with moderately to severely active Crohn’s disease: Phase 3 GRAVITI studyECCO'25Year: 2025
Authors: Sands, B.(1);Danese, S.(2);Cao, Q.(3);Steinwurz, F.(4);Kierkus, J.(5);Han, C.(6);Olurinde, M.(6);Yang, Z.(6);Merrall, E.(7);Terry, N.A.(6);Hart, A.(8)*;
(1)Icahn School of Medicine at Mount Sinai- New York- NY- USA, na, New York, United States;(2)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele- Milano- Italy, na, Milano, Italy;(3)Sir Run Run Shaw Hospital Affiliated with School of Medicine- Zhejiang University- Hangzhou- China, na, Hangzhou, China;(4)Pan American Crohn’s and Colitis Organisation- São Paulo- Brazil, na, Sao Paulo, Brazil;(5)Department of Gastroenterology- Hepatology- Feeding Disorders and Pediatrics- The Children's Memorial Health Institute- Warsaw- Poland, na, Warsaw, Poland;(6)Janssen Research & Development- LLC- Spring House- PA- USA, na, Spring House, United States;(7)Janssen Vaccines and Prevention BV- Leiden- The Netherlands, na, Leiden, The Netherlands;(8)London North-West University Healthcare NHS Trust- London- United Kingdom, na, London, United Kingdom;
1. Cohen RD. The quality of life in patients with Crohn’s disease. Aliment Pharmacol Ther. 2002;16(9):1603-1609.
2. Moradkhani A, Beckman LJ, Tabibian JH. Health-related quality of life in inflammatory bowel disease: psychosocial, clinical, socioeconomic, and demographic predictors. J Crohns Colitis. 2013;7(6):467-473.
3. Kalafateli M, Triantos C, Theocharis G, et al. Health-related quality of life in patients with inflammatory bowel disease: a single-center experience. Ann Gastroenterol. 2013;26(3):243-248.
4. Sands BE, Panés J, Feagan BG, et al. Qualitative and psychometric evaluation of 29-item Patient-Reported Outcomes Measurement Information System® to assess general health-related quality of life in patients with moderately to severely active inflammatory bowel disease. Value Health. 2024;27(9):1225-1234
P1150: Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled studyECCO'25Year: 2025
Authors: Albshesh, A.(1)*;Kucha, P.(2);Pugliese, D.(3);Amiot , A.(4);Mahajna, H.(1,5);Eder, P.(6);V. Savarino , E.(7);Vavricka, S.(8);Castiglione, F.(9);Imperatore, N.(10);Krznaric, Z.(11);Abitbol , C.M.(1);Hen, O.(12);Zaborowska , M.(2);Carbonnel , F.(4);Cuccia , G.(3);Lorenzon , G.(7);Zittan , E.(5);Zagórowicz , E.(2);Maniero , D.(7);Ben-Horin , S.(1);Kopylov , U.(1);
(1)Sheba Medical Center Tel Hashomer- Sackler School of Medicine- Tel-Aviv University- Tel Aviv- Israel, Department of Gastroenterology, Ramat Gan, Israel;(2)The Maria Sklodowska-Curie National Research Institute of Oncology- Warsaw- Poland and Department of Gastroenterology- Hepatology and Clinical Oncology- Centre of Postgraduate Medical Education- Warsaw- Poland, Department of Oncological Gastroenterology, Warsaw, Poland;(3)Università Cattolica del Sacro Cuore- L. Go A. Gemelli 8- 00168 Rome- Italy, Dipartimento di Medicina e Chirurgia Traslazionale, Rome, Italy;(4)Assistance Publique-Hôpitaux de Paris- Université Paris Saclay- France, Service de Gastroentérologie CHU Bicêtre, Paris, France;(5)Emek Medical Center- Afula- The Rappaport Faculty of Medicine Technion-Israel Institute of Technology- Haifa- Israel, The Abraham and Sonia Rochlin IBD Unit- Department of Gastroenterology, Emek, Israel;(6)Poznań University of Medical Sciences- University Clinical Hospital- Poznan- Poland, Department of Gastroenterology- Dietetics and Internal Medicine, Poznan, Poland;(7)DiSCOG University of Padua Azienda Ospedaliera di Padova-Italy, Department of Surgery- Oncology and Gastroenterology, Padua, Italy;(8)Vulkanplatz 8- CH- 8048 Zurich- Switzerland, Center for Gastroenterology and Hepatology, Zurich, Switzerland;(9)University Federico II of Naples- 80126 Naples- Italy, Gastroenterology Unit- Department of Clinical Medicine and Surgery, Naples, Italy;(10)Santa Maria delle Grazie Hospital- Pozzuoli- Naples- Italy, Gastroenterology and Endoscopy Unit, Naples, Italy;(11)University Hospital Zagreb- Zagreb- Croatia, Department of Gastroenterology- Hepatology and Nutrition, Zagreb, Croatia;(12)Sheba Medical Center- Tel Hashomer- Israel, Internal Medicine Department C, Ramat Gan, Israel;
P1151: 6-month real-world results from the prospective FilgoColitis study on clinical effectiveness and psycho-social outcomesECCO'25Year: 2025
Authors: Plachta-Danielzik, S.(1)*;Bokemeyer, B.(1,2,3);Hellms, T.(4);Landry, W.(5);Kahl, M.(6);Ehehalt, R.(7);Zimmermann, L.(8);Schiffelholz, A.(9);Efken, P.(10);Reiner, J.(11);Fajardo Salmon, S.(1);Wenske, T.(1);Schreiber, S.(1,2);
(1)Competence network IBD, Study department, Kiel, Germany;(2)University Hospital Schleswig-Holstein- Campus Kiel, Clinic of General Internal Medicine I, Kiel, Germany;(3)Interdisciplinary Crohn Colitis Centre Minden, Gastroenterology, Minden, Germany;(4)Medical Hospital Hannover MHH, Clinic for gastroenterology- hepathology and endocrinology, Hannover, Germany;(5)Medical care centre Dachau, Gastroenterology, Dachau, Germany;(6)Gastroenterology practice, Gastroenterology, Hamburg, Germany;(7)Gastroenterology practice, Gastroenterology, Heidelberg, Germany;(8)Gastroenterology practice, Gastroenterology, Magdeburg, Germany;(9)Gastroenterology practice, Gastroenterology, Augsburg, Germany;(10)Gastroenterology practice, Gastroenterology, Minden, Germany;(11)University Medical Center Rostock, Internal Medicine - Gastroenterology, Rostock, Germany;
P1152: Single center study of using clinical decision support tool to predict outcomes of vedolizumab therapy in Crohn’s disease patientsECCO'25Year: 2025
Authors: Konecny, S.(1,2)*;Tichanek, F.(3);Prokopova, L.(1,2);Kavrikova, P.(1,2);Zvarova, V.(1,2);Poredska, K.(1,2);Zboril, V.(1,2);
(1)University Hospital Brno, Internal Gastroenterology Department, Brno, Czech Republic;(2)Masaryk University, Faculty of Medicine, Brno, Czech Republic;(3)Institute for Clinical and Experimental Medicine, Department of Data Science, Prague, Czech Republic;
1. Dulai PS, Boland BS, Singh S, et al. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. Gastroenterology. 2018;155(3):687-695.e10.
P1153: Intestinal Fibrosis Attenuates the Prophylactic Effect of Antitumour Necrosis Factor Therapy on Postoperative Recurrence of Crohn’s DiseaseECCO'25Year: 2025
Authors: Ding, Z.(1);Wang, Y.(1);Zhang, M.(1);Li, Y.(1)*;
(1)Shanghai Ninth People's Hospital- Shanghai Jiao Tong University School of Medicine, Department of General Surgery, Shanghai, China;
P1154: Impact of pharmacological therapies for moderate to severe Ulcerative Colitis on health-related quality of life: a systematic review and network meta-analysisECCO'25Year: 2025
Authors: Katsoula, A.(1,2)*;Paschos, P.(2,3);Malandris, K.(2);Giouleme, O.(1);Tsapas, A.(2,4);
(1)Aristotle University of Thessaloniki, Hippokration Hospital- Gastroenterology Division-Second Propaedeutic Department of Internal Medicine-Medical School, Thessaloniki, Greece;(2)Clinical Research and Evidence-Based Medicine Unit, Second Medical Department- Aristotle University of Thessaloniki, Thessaloniki, Greece;(3)“Papageorgiou” Hospital, First Department of Internal Medicine, Thessaloniki, Greece;(4)Harris Manchester College, University of Oxford, Oxford, United Kingdom; This study was funded by a research grant 2020EOMIFNEp5 from the Hellenic Group for the Study of IBD (EOMIFNE)
P1155: Safety of Venous Thromboembolism Pharmacological Prophylaxis in Hospitalized Patients with Inflammatory Bowel Disease; A Single Center Retrospective Study (VISCOUS)ECCO'25Year: 2025
Authors: Alrashed , F.(1);Safar, F.(2);Alrewai, A.(2);Mohammad, S.(2);Aldeai, A.(2);Alenezi, O.(2);Shehab, M.(3)*;
(1)Kuwait University, Department of Pharmacy Practice, Jabriya, Kuwait;(2)Mubarak Al-Kabeer University Hospital, Department of Internal Medicine, Kuwait, Kuwait;(3)Mubarak Al-Kabeer University Hospital - Jabrya- Kuwait., Department of Internal Medicine, Kuwait, Kuwait;
- Pleet JL, Vaughn BP, Morris JA, et al. The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis. Aliment Pharmacol Ther [Internet]. 2014;39(9):940–948.
- Dawwas GK, Cuker A, Schaubel DE, et al. Effectiveness and safety of prophylactic anticoagulation among hospitalized patients with inflammatory bowel disease. Blood Adv [Internet]. 2024;8(5):1272–1280.
- Kaddourah O, Numan L, Jeepalyam S, et al. Venous thromboembolism prophylaxis in inflammatory bowel disease flare-ups. Ann Gastroenterol. 2019;32(6):578–583.
P1156: Fidaxomicin for Clostridiodes difficile infection in inflammatory bowel disease: a multicenter retrospective cohort studyECCO'25Year: 2025
Authors: Noviello, D.(1)*;Chaparro, M.(2);Viganò, C.(3);Blesl, A.(4);Barberio, B.(5);Yanai, H.(6);Macaluso, F.(7);Ferreiro-Iglesias, R.(8);Bezzio, C.(9);Zilli, A.(10);Molnár, T.(11);Gheorghe, C.(12);Conforti, F.S.(13);Innocenti, T.(14);Saibeni, S.(15);Bossuyt, P.(16);de Oliveira, R.F.(17);Carvalhas Gabrielli, A.M.(18);Losco, A.(19);Vieujean, S.(20);Tettoni, E.(21);Pirola, L.(22);Calderone, S.(7);Kornowski Cohen, M.(23);Dragoni, G.(14);Rath, T.(24);Barreiro-de Acosta, M.(8);Savarino, E.V.(5);Gisbert, J.P.(25);Vecchi, M.(1);Atreya, R.(24);Caprioli, F.(26);
(1)University of Milan, Department of Pathophysiology and Transplantation, Milano, Italy;(2)Universidad Autónoma de Madrid, Gastrointestinal Units of Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBE, Madrid, Spain;(3)Fondazione IRCCS San Gerardo dei Tintori, Division of Gastroenterology- Center for Autoimmune Liver Diseases- Department of Medicine and Surgery- University of Milano-Bicocca- European Reference Network on Hepatological Diseases ERN RARE-LIVER, Monza, Italy;(4)Medical University of Graz, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Graz, Austria;(5)University of Padova, Division of Gastroenterology- Department of Surgery Oncology and Gastroenterology DiSCOG, Padova, Italy;(6)Rabin Medical Center- Tel Aviv University, Division of Gastroenterology- Faculty of Medicine, Petah-Tikva, Israel;(7)"Villa Sofia-Cervello" Hospital, Inflammatory bowel disease Unit, Palermo, Italy;(8)Complejo Hospitalario Universitario de Santiago, Gastroenterology Department, Santiago de Compostela- La Coruña, Spain;(9)IRCCS Humanitas Research Hospital, Department of Biomedical Sciences- Humanitas University, Rozzano, Italy;(10)IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Department of Gastroenterology and Endoscopy, Milan, Italy;(11)Albert Szent-Györgyi Medical School- University of Szeged, Department of Internal Medicine, Szeged, Hungary;(12)Fundeni Clinical Institute- Carol Davila University of Medicine and Pharmacy, Center of Gastroenterology and Hepatology- Faculty of Medicine, Bucharest, Romania;(13)Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Gastroenterology and Endoscopy Unit, Milano, Italy;(14)Careggi University Hospital- University of Florence, IBD Referral Center- Clinical Gastroenterology Unit- Department of Experimental and Clinical Biochemical Sciences "Mario Serio"- University of Florence, Florence, Italy;(15)ASST Rhodense, IBD Centre- Gastroenterology Unit- Rho Hospital, Rho, Italy;(16)Imelda General Hospital, Imelda GI Clinical Research Center, Bonheiden, Belgium;(17)Unidade Local de Saúde do Algarve- Portimão Unit-, Gastroenterology Department, Algarve, Portugal;(18)ASST Fatebenefratelli-Sacco- L. Sacco Hospital, Gastroenterology Unit, Milano, Italy;(19)ASST Santi Paolo e Carlo- Ospedale San Carlo, Gastroenterology Unit, Milano, Italy;(20)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;(21)Fondazione Poliambulanza Istituto Ospedaliero- Fondazione Policlinico Universitario A. Gemelli IRCCS, Gastroenterology and Digestive Endoscopy Unit- Università Cattolica del Sacro Cuore, Brescia, Italy;(22)Fondazione IRCCS San Gerardo dei Tintori- University of Milano-Bicocca, Division of Gastroenterology- Center for Autoimmune Liver Diseases- Department of Medicine and Surgery- European Reference Network on Hepatological Diseases ERN RARE-LIVER, Monza, Italy;(23)Rabin Medical Center- Tel Aviv University, Division of Gastroenterology- Faculty of Medicine, Tel Aviv, Israel;(24)Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Department of Medicine 1, Erlangen, Germany;(25)Instituto de Investigación Sanitaria Princesa IIS-Princesa- Universidad Autónoma de Madrid UAM- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastrointestinal Unit of Hospital Universitario de La Princesa, Madrid, Spain;(26)University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy;
P1157: Limited Willingness to Switch from Intravenous to Subcutaneous treatment in Pediatric Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Richter, V.(1)*;Eindor-Abarbanel, A.(2);Shalem , T.(2);Weiss, B.(3);Cohen, D.L.(2);Shalev-Shamay, R.(4);Yerushalmi, B.(4);Yerushalmy-Feler, A.(5);Topf Olivestone, C.(6);Shirin, H.(2);Broide, E.(2);
(1)Shamir Medical Center, Gastroenterology, Beit Elazari, Israel;(2)Shamir medical center, Gastroenterology, Zerifin, Israel;(3)Safra Children's Hospital Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel;(4)Soroka Medical Center, Gastroenterology, Beer Sheva, Israel;(5)Dana-Dwek Children's Hospital, Gastroenterology, Tel aviv, Israel;(6)Assuta medical center, Gastroenterology, Ashdod, Israel;
P1158: Patients with refractory and difficult-to-treat Inflammatory Bowel Disease are underrepresented in randomized clinical trialsECCO'25Year: 2025
Authors: ParigiMD, T.L.(1,2,3)*;Solitano, V.(4,5);Mekonnen, H.(5);Yuan, Y.(5);Jairath, V.(5);Danese, S.(3);
(1)IRCCS San Raffaele Hospital, Department of Gastroenterology and Endoscopy, Milan, Italy;(2)Case Western Reserve University, Department of Pathology, Cleveland- Ohio, United States;(3)University Vita-Salute San Raffaele, Division of Immunology- Transplantation and Infectious Disease, Milan, Italy;(4)Università Vita-Salute San Raffaele, Division of Immunology- Transplantation and Infectious Disease, Milano, Italy;(5)Western University, Department of Medicine- Division of Gastroenterology, London- Ontario, Canada;
1. Parigi TL, et al. Lancet Gastroenterol Hepatology 2023
2. Sedano R, et al. Journal Crohn & Colitis 2021
3. Almradi A, et al. Journal Crohn & Colitis 2021
P1159: New onset acne reported in the majority of patients with upadacitinib-treated Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Omrani, F.(1)*;Sharma, E.(1);Irving, P.(1);Ray, S.(1);Anderson , S.(1);Mawdsley , J.(1);Dart, R.(1);Samaan, M.(1);Gecse, K.(1);
(1)Guy's and St Thomas' NHS Trust, Gastroenterology, London, United Kingdom;
P1160: Real-world comparative safety of filgotinib and upadacitinib for ulcerative colitis: a propensity score matchingECCO'25Year: 2025
Authors: Nogami, A.(1,2)*;Asonuma, K.(1);Okabayashi, S.(3);Ikenouchi, M.(4);Shinzaki, S.(4);Fukata, M.(5);Kobayashi, T.(1,2,6);
(1)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(2)Kitasato University Kitasato Institute Hospital, Department of Gastroenterology and Hepatology, Tokyo, Japan;(3)Kyoto University Graduate School of Medicine, Department of Healthcare Epidemiology, Kyoto, Japan;(4)School of Medicine- Hyogo Medical University, Department of Gastroenterology, Hyogo, Japan;(5)Tokyo Yamate Medical Center, Center for Inflammatory Bowel Disease- Division of Gastroenterology- Department of Internal Medicine, Tokyo, Japan;(6)Kitasato University School of Medicine, Department of Gastroenterology, Kanagawa, Japan;
1. Nogami.A, Asonuma K, Okabayashi S, et al. United European Gastroenterol J. 2024 Nov 13.
P1161: Effects of janus-kinase inhibitor therapy on lipid parameters in patients with IBDECCO'25Year: 2025
Authors: Prabhu, A.(1)*;Al Dehailan, R.(1);Azzu, H.(1);Sanford, J.(1);Cripps, S.(1);Scaria, L.(1);Walsh, A.(1);
(1)Oxford University Hospitals NHS Foundation Trust, Translational Gastroenterology Unit, Oxford, United Kingdom;
1. Li N, Gou ZP, Du SQ et al. Effect of JAK inhibitors on high- and low-density lipoprotein in patients with rheumatoid arthritis: a systematic review and network meta-analysis. Clin Rheumatol. 2022;41(3):677-88.
2. Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41(5):837-52.
3. Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303-11.
4. Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, et al. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. JAMA. 2019;322(4):315-25.
P1162: Novel use of risankizumab in children with refractory Crohn’s disease : Case seriesECCO'25Year: 2025
Authors: Alsarhan, A.(1)*;Tzivinikos, C.(1);
(1)Al Jalila Children's hospital, Pediatric Gastroenterology, Dubai, United Arab Emirates;
Zare B, Gros B, Lal N, et alEffectiveness of risankizumab induction and maintenance therapy for refractory Crohn’s disease: a real-world experience from a preapproval access programme and early access to medicines schemeFrontline Gastroenterology 2024;15:499-506.
P1163: Treatment-based risk stratification of serious and opportunistic infections in IBD patients from an tertiary center in brazil: a comparison between advanced therapies and non-biologic exposure in real world settingECCO'25Year: 2025
Authors: Chebli, J.(1)*;Chebli, L.(1);Ricci Jr, J.E.(1);Tarsila, R.(1);Andrade Chebli, V.(2);Ferreira Lima, G.(2);Carvalho Roland, A.(2);Gaburri Martins, A.B.(3);
(1)Universidade Federal de Juiz de Fora, IBD Center, Juiz de Fora, Brazil;(2)Faculdade de Ciências Médicas e da Saúde de Juiz de Fora, Clínica Médica, Juiz de Fora, Brazil;(3)Universidade Metropolitana de Santos, Clínica Médica, Santos, Brazil;
1. José da Silva R, da Rocha Ribeiro TC, Chebli LA, Chebli JMF. An Unexpected Cause of Headache and Splenic Lesions During Anti-TNF Therapy in Crohn Disease. Inflamm Bowel Dis. 2021; 27(1):e1-e2.
2. Bonovas S, Fiorino G, Allocca M, Lytras T, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385-1397.e10.
3. Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020;18:69-81.e3.
4. Solitano V, Facciorusso A, Jess T, Ma C, Hassan C, Repici A, Jairath V, Armuzzi A, Singh S. Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2023;21(4):907-921.e2
P1164: Consumption of red and processed meat may be associated with fatigue and anxiety in patients with IBDECCO'25Year: 2025
Authors: Hardt, H.(1)*;Wilke, E.(1);Herrmann, E.K.(1);Reindl, W.(1);Thomann, A.(1);
(1)Medical Faculty Mannheim- Heidelberg University, Department of Medicine II, Mannheim, Germany;
P1165: Longitudinal observation of symptoms of fatigue, depression and anxiety in Crohn’s diseaseECCO'25Year: 2025
Authors: Stephan, J.C.(1)*;Atanasova, K.(2);Knoedler, L.L.(1);Ebert, M.P.(1);Reindl, W.(1);Wolf, R.C.(3);Thomann, A.K.(1);
(1)Medical Faculty Mannheim- Heidelberg University, Department of Medicine II, Mannheim, Germany;(2)Central Institute of Mental Health- Medical Faculty Mannheim- Heidelberg University, Institute of Psychiatric and Psychosomatic Psychotherapy, Mannheim, Germany;(3)Heidelberg University Hospital- Heidelberg University, Department of General Psychiatry, Heidelberg, Germany;
P1166: Factors associated with mesalamine refractory Ulcerative Proctitis requiring advanced medical treatmentsECCO'25Year: 2025
Authors: Borkovsky, T.(1)*;Cohen, N.A.(1);Bannon , L.(1);Hirsch, A.(1);Ron, Y.(1);Thurm, T.(1);Maharshak, N.(1);Leibovitzh, H.(1);
(1)Tel Aviv University- Faculty of Medicine, Tel Aviv Sourasky Medical Center- IBD Center- Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel;
P1167: Treatable traits (TTs) approach in the management of Inflammatory Bowel Disease: a new conceptECCO'25Year: 2025
Authors: Facanali , C.(1)*;Sobrado , C.W.(2);RF Carvalho , C.(3);
(1)Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo- HCFMUSP, Department of Gastroenterology and Division of Colorectal Surgery, Sao Paulo, Brazil;(2)Hospital das Clinicas da Faculdade de medicina da Universidade de Sao Paulo, Gastroenterologia- divisão de coloproctologia, Sao Paulo, Brazil;(3)Hospital das Clinicas da Faculdade de medicina da Universidade de Sao Paulo, 3. Departamento de Fisioterapia e Fisiologia do Exercício LIFFE, Sao Paulo, Brazil;
References
- Le Berre C, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L. Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. Clin Gastroenterol Hepatol. 2020 Jan;18(1):14-23. doi: 10.1016/j.cgh.2019.07.005. Epub 2019 Jul 10. PMID: 31301452.
2. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19. PMID: 33359090.
3. Agusti A, Gibson PG, McDonald VM. Treatable Traits in Airway Disease: From Theory to Practice. J Allergy Clin Immunol Pract. 2023 Mar;11(3):713-723. doi: 10.1016/j.jaip.2023.01.011. Epub 2023 Feb 1. PMID: 36737342.
4. Amati F, Bongiovanni G, Tonutti A, Motta F, Stainer A, Mangiameli G, Aliberti S, Selmi C, De Santis M. Treatable Traits in Systemic Sclerosis. Clin Rev Allergy Immunol. 2023 Oct;65(2):251-276. doi: 10.1007/s12016-023-08969-x. Epub 2023 Aug 21. PMID: 37603199.
P1168: Real-world evidence comparison of the effectiveness of ustekinumab with anti-TNF or vedolizumab in ulcerative colitis: 2-year maintenance therapy results from the prospective, observational RUN-UC studyECCO'25Year: 2025
Authors: Bokemeyer, B.(1)*;Plachta-Danielzik, S.(2);Howaldt, S.(3);Mohl, W.(4);Efken, P.(5);Ehehalt, R.(6);Kahl, M.(7);Krause, T.(8);Trentmann, L.(9);Lügering, A.(10);Schnoy, E.(11);Jochum, C.(12);Fajardo Salmon, S.(2);Hartmann, P.(13);Gilman, E.(2);Schreiber, S.(14);
(1)Interdisciplinary Crohn Colitis Centre Minden, Gastroenterology, Minden, Germany;(2)Competence Network IBD, Study Department, Kiel, Germany;(3)Research Institute for IBD-HaFCED- Hamburg, Gastroenterology, Hamburg, Germany;(4)Centre for Gastroenterology Saar MVZ, Gastroenterology, Saarbrücken, Germany;(5)Gastroenterology Practice Minden, Gastroenterology, Minden, Germany;(6)Gastroenterology Practice Heidelberg, Gastroenterology, Heidelberg, Germany;(7)Gastroenterology Practice Hamburg, Gastroenterology, Hamburg, Germany;(8)Gastroenterology Practice Kassel, Gastroenterology, Kassel, Germany;(9)Gastroenterology Practice Bremen, Gastroenterology, Bremen, Germany;(10)Gastroenterology Practice Münster, Gastroenterology, Münster, Germany;(11)University Hospital Augsburg, III. Medical Clinic, Augsburg, Germany;(12)Charite University Hospital Berlin- Campus Mitte, Department of Hepatology and Gastroenterology, Berlin, Germany;(13)Gastroenterology Practice Minden, Study Department, Minden, Germany;(14)University Hospital Schleswig-Holstein Campus Kiel, Clinic of General Internal Medicine I, Kiel, Germany;